The european medicines agency (ema) has approved an additional subcutaneous administration option for takhzyro® (lanadelumab) for patients aged 12 years and above with recurrent attacks of hereditary angioedema (hae)

Takhzyro solution for injection in 2 ml pre-filled pen is now approved to facilitate subcutaneous administration in adolescent (aged 12 years and above) and adult patients with hae.1 the pre-filled pen option is designed to allow for an individualized treatment approach for adolescent and adult hae patients. in the eu, takhzyro is approved for routine prevention of recurrent hae attacks in patients aged 2 years and older.1 zurich , feb. 24, 2025 /prnewswire/ -- takeda (tse: 4502) (nyse: tak) announced today that the ema has approved an additional 2 ml pre-filled pen option for takhzyro® (lanadelumab) for subcutaneous administration in adolescents (aged 12 years and above) and adult patients with hereditary angioedema (hae).1 the additional subcutaneous administration option expands takeda's offering in this space, showing dedication to the hae community while providing individualized treatment options to support patients with a life-threatening disease, by helping to reduce hae burden and improving their quality of life.
TAK Ratings Summary
TAK Quant Ranking